mrna microarray experiments (CapitalBio Corporation)
90
Structured Review
CapitalBio Corporation
mrna microarray experiments
Mrna Microarray Experiments, supplied by CapitalBio Corporation, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/mrna+microarray+analysis/pmc06426711-187-18-30?v=CapitalBio+Corporation
Average 90 stars, based on 1 article reviews
Mrna Microarray Experiments, supplied by CapitalBio Corporation, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/mrna+microarray+analysis/pmc06426711-187-18-30?v=CapitalBio+Corporation
Average 90 stars, based on 1 article reviews
mrna microarray experiments - by Bioz Stars,
2026-08
90/100 stars
Images
1) Product Images from "MicroRNA-26b-5p Inhibits Mouse Liver Fibrogenesis and Angiogenesis by Targeting PDGF Receptor-Beta"
Article Title: MicroRNA-26b-5p Inhibits Mouse Liver Fibrogenesis and Angiogenesis by Targeting PDGF Receptor-Beta
Journal: Molecular Therapy. Nucleic Acids
doi: 10.1016/j.omtn.2019.02.014
Figure Legend Snippet: The Expression Pattern of PDGFR-β in the Fibrotic Liver of MCDHF Mice and the Correlation between PDGFR-β and Fibrosis and Angiogenesis Markers (A) Representative H&E, Sirius Red, and oil red O stainings in the fibrotic liver of MCDHF mice. The mRNA expressions of fibrosis markers (B), angiogenesis markers (C), and PDGFR-β (D) were examined by qRT-PCR in the fibrotic liver of MCDHF mice. PDGFR-β protein expression was examined (E) and quantified (F) by western blot in the fibrotic liver. Data are presented as the mean ± SEM. n = 6 per group. *p < 0.05 versus control.
Techniques Used: Expressing, Quantitative RT-PCR, Western Blot, Control
Figure Legend Snippet: The Origin of PDGFR-β + Cells in MCDHF Fibrotic Mice and the Expression of PDGFR-β in TGF-β1-Treated BMSCs In Vivo (A) Representative images of immunofluorescence analysis to track PDGFR-β (green) expression in the fibrotic liver. Hollow arrows indicate PDGFR-β expression around the newly formed vessels, while solid arrows indicate PDGFR-β expression around the existing mature vessels. (B) Immunofluorescence staining for PDGFR-β (red) to track PDGFR-β + cells following 56 days of MCDHF diet. (C) The proportion of PDGFR-β + EGFP + cells accounting for total PDGFR-β + cells was measured by Image-Pro Plus software. (D) PDGFR-β mRNA expression was examined by qRT-PCR in BMSCs treated with the indicated concentrations of TGF-β1 for 24 h. (E) PDGFR-β mRNA expression in BMSCs treated with 10 ng/mL TGF-β1 at different times. (F and G) PDGFR-β protein expression was examined (F) and quantified (G) by western blot in TGF-β1-treated BMSCs. Data are presented as the mean ± SEM. n = 6 per group. *p < 0.05 versus control.
Techniques Used: Expressing, In Vivo, Immunofluorescence, Staining, Software, Quantitative RT-PCR, Western Blot, Control
Figure Legend Snippet: Downregulation of PDGFR-β Expression by miR-26b-5p in TGF-β1-Treated BMSCs (A) miR-26b-5p expression in the fibrotic liver induced by MCDHF. (B) The correlation between miR-26b-5p and PDGFR-β in liver tissue. Transfection efficiency of miR-26b-5p mimic (C) or inhibitor (F) in BMSCs is shown. PDGFR-β mRNA expression was examined by qRT-PCR with or without miR-26b-5p mimic (D) or inhibitor (G) transfection in BMSCs. Protein expression was examined by western blot with miR-26b-5p mimic (E) or inhibitor (H) transfection in BMSCs. Biotin-avidin pull-down assay (I) and luciferase reporter assay (J) demonstrated PDGFR-β was a target of miR-26b-5p. Data are presented as the mean ± SEM. n = 6 per group. *p < 0.05 versus control. #p < 0.05 versus TGF-β1 treated alone.
Techniques Used: Expressing, Transfection, Quantitative RT-PCR, Western Blot, Avidin-Biotin Assay, Pull Down Assay, Luciferase, Reporter Assay, Control
Figure Legend Snippet: Regulation of lncMEG3 on PDGFR-β in TGF-β1-Treated BMSCs (A) lncMEG3 expression was examined by qRT-PCR in the fibrotic liver induced by MCDHF. (B) The correlation between lncMEG3 and PDGFR-β in liver tissue. Transfection efficiency of lncMEG3 overexpression plasmid (C) or siRNA (F) in BMSCs is shown. PDGFR-β mRNA expression was examined by qRT-PCR with lncMEG3 overexpression plasmid (D) or siRNA (G) in BMSCs. PDGFR-β protein expression was examined by western blot with lncMEG3 overexpression plasmid (E) or siRNA (H) in BMSCs. Data are presented as the mean ± SEM. n = 6 per group. *p < 0.05 versus control. #p < 0.05 versus TGF-β1 treated alone.
Techniques Used: Expressing, Quantitative RT-PCR, Transfection, Over Expression, Plasmid Preparation, Western Blot, Control
Figure Legend Snippet: miR-26b-5p Was Sponged by lncMEG3 in TGF-β1-Treated BMSCs (A) The correlation between lncMEG3 and miR-26b-5p in liver tissue. Biotin-avidin pull-down assay (B) and luciferase reporter assay (C) demonstrated that lncMEG3 was a target of miR-26b-5p. (D) PDGFR-β mRNA expression with or without lncMEG3 overexpression plasmids in miR-26b-5p mimic-treated BMSCs. (E) PDGFR-β protein expression with or without lncMEG3 overexpression plasmids in miR-26b-5p mimic-treated BMSCs. Data are presented as the mean ± SEM. n = 6 per group. *p < 0.05 versus control. #p < 0.05 versus miR-26b-5p mimic treated alone.
Techniques Used: Avidin-Biotin Assay, Pull Down Assay, Luciferase, Reporter Assay, Expressing, Over Expression, Control
Figure Legend Snippet: Microarray Analysis Was Performed in TGF-β1-Treated BMSCs with or without miR-26b-5p Mimics BMSCs were treated with 10 ng/mL TGF-β1 for 24 h with or without miR-26b-5p mimics. Microarray analysis for mRNA was performed with RNA extracted from BMSCs. Hierarchical cluster analysis of significantly differentially expressed mRNA is shown as follows: bright green, underexpression; black, no change; bright red, overexpression. n = 3 per group. (A) Microarray heatmap comparing the signatures of PDGFR-β and angiogenesis marker and fibrosis marker genes in TGF-β1-treated BMSCs with or without miR-26b-5p mimics. KEGG and Reactome enrichment analyses (B) and GO enrichment analysis for biological process terms (C) are for the differentially expressed genes with miR-26b-5p mimics. n = 3 per group. (D) Predicted protein network visualization with STRING. The network view predicted the associations between proteins from the regulated genes involved in angiogenesis and extracellular matrix organization in TGF-β1-treated BMSCs. The network nodes were proteins. These proteins were clustered using k-means clustering algorithms.
Techniques Used: Microarray, Over Expression, Marker
Figure Legend Snippet: The Regulation of miR-26b-5p Agomir on PDGFR-β Expression, Liver Fibrosis, and Angiogenesis In Vivo (A) Transfection efficiency of 50 nM miR-26b-5p agomir (mimic in vivo ) in the fibrotic liver of MCDHF mice. (B) PDGFR-β mRNA levels in liver tissue were measured by qRT-PCR with or without miR-26b-5p agomir injection in MCDHF mice. (C) PDGFR-β protein levels in liver tissue were measured by western blot. (D) Representative images of immunofluorescence analysis to track PDGFR-β (red) expression in BMSCs (green) in the fibrotic liver. (E) The proportion of PDGFR-β + EGFP + cells of total PDGFR-β + cells was measured by Image-Pro Plus software. Hollow arrows indicate PDGFR-β − EGFP + cells, while solid arrows indicate PDGFR-β + EGFP + cells. DAPI was used to visualize nuclei (blue). The mRNA levels of angiogenesis markers (F) and fibrosis markers (G) in the fibrotic liver are shown. Data are presented as the mean ± SEM. n = 6 per group. *p < 0.05 versus control. #p < 0.05 versus MCDHF treated alone.
Techniques Used: Expressing, In Vivo, Transfection, Quantitative RT-PCR, Injection, Western Blot, Immunofluorescence, Software, Control
